{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:53:53Z","timestamp":1771268033025,"version":"3.50.1"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.2169\/internalmedicine.2882-19","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T18:03:02Z","timestamp":1565028182000},"page":"3461-3468","source":"Crossref","is-referenced-by-count":8,"title":["Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone"],"prefix":"10.2169","volume":"58","author":[{"given":"Sho","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Komatsuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Ubukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Crow RS. Peripheral neuritis in myelomatosis. Br Med J 2: 802-804, 1956.","DOI":"10.1136\/bmj.2.4996.802"},{"key":"2","unstructured":"2. Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore) 59: 311-322, 1980."},{"key":"3","unstructured":"3. Takatsuki K, Sanada I. Plasma cell dyscrasia with polyneuropathy and endocrine disorder: clinical and laboratory features of 109 reported cases. Jpn J Clin Oncol 13: 543-555, 1983."},{"key":"4","unstructured":"4. Misawa S, Sato Y, Katayama K, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 15: 1129-1137, 2016."},{"key":"5","unstructured":"5. Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol 179: 748-755, 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Li J, Huang XF, Cai QQ, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol 93: 803-809, 2018.","DOI":"10.1002\/ajh.25100"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jelinek T, Bezdekova R, Zatopkova M, et al. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J 7: e617, 2017.","DOI":"10.1038\/bcj.2017.90"},{"key":"8","unstructured":"8. Dao LN, Hanson CA, Dispenzieri A, Morice WG, Kurtin PJ, Hoyer JD. Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients. Blood 117: 6438-6444, 2011."},{"key":"9","unstructured":"9. Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 92: 814-829, 2017."},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. D&apos;Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 120: 56-62, 2012.","DOI":"10.1182\/blood-2012-04-423178"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ben Lassoued A, Nivaggioni V, Gabert J. Minimal residual disease testing in hematologic malignancies and solid cancer. Expert Rev Mol Diagn 14: 699-712, 2014.","DOI":"10.1586\/14737159.2014.927311"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 149: 334-351, 2010.","DOI":"10.1111\/j.1365-2141.2010.08121.x"},{"key":"13","unstructured":"13. Olteanu H, Harrington AM, Kroft SH. CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma. Am J Clin Pathol 138: 867-876, 2012."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Binder M, Bacher U. The role of CD81 for plasma cell dyscrasias. Leuk Res 38: 292-293, 2014.","DOI":"10.1016\/j.leukres.2013.12.026"},{"key":"15","unstructured":"15. Guikema JE, Hovenga S, Vellenga E, et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol 121: 36-43, 2003."},{"key":"16","unstructured":"16. Arana P, Paiva B, Cedena MT, et al. Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia 32: 971-978, 2018."},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. D&apos;Souza A, Hayman SR, Buadi F, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 118: 4663-4665, 2011.","DOI":"10.1182\/blood-2011-06-362392"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hashiguchi T, Arimura K, Matsumuro K, et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 23: 1051-1056, 2000.","DOI":"10.1002\/1097-4598(200007)23:7<1051::AID-MUS7>3.0.CO;2-V"},{"key":"19","unstructured":"19. Soubrier MJ, Dubost JJ, Sauvezie BJ; French Study Group on POEMS Syndrome. POEMS syndrome: a study of 25 cases and a review of the literature. Am J Med 97: 543-553, 1994."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 101: 2496-2506, 2003.","DOI":"10.1182\/blood-2002-07-2299"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Abe D, Nakaseko C, Takeuchi M, et al. Restrictive usage of monoclonal immunoglobulin lambda light chain germline in POEMS syndrome. Blood 112: 836-839, 2008.","DOI":"10.1182\/blood-2007-12-126979"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kawajiri-Manako C, Mimura N, Fukuyo M, et al. Clonal immunoglobulin \u03bb light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome. Am J Hematol 93: 1161-1168, 2018.","DOI":"10.1002\/ajh.25213"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Romas E, Storey E, Ayers M, Byrne E. Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin change (POEMS) syndrome with IgG kappa paraproteinemia. Pathology 24: 217-220, 1992.","DOI":"10.3109\/00313029209063178"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Dursun B, Artac M, Varan HI, Akkaya BK, Karpuzoglu G, Suleymanlar G. An atypical case of POEMS syndrome with IgG kappa M protein and end stage renal failure. Int Urol Nephrol 37: 581-585, 2005.","DOI":"10.1007\/s11255-004-0008-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sethi S, Tageja N, Arabi H, Penumetcha R. Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction. South Med J 102: 1092-1093, 2009.","DOI":"10.1097\/SMJ.0b013e3181b2f7d8"},{"key":"26","unstructured":"26. Pulivarthi S, Gurram MK. An atypical presentation of POEMS syndrome with IgG kappa type M protein and normal VEGF level: Case report and review of literature. J Cancer Res Ther 14: 679-681, 2018."},{"key":"27","unstructured":"27. Ye W, Wang C, Cai QQ, et al. Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome. Nephrol Dial Transplant 31: 275-283, 2016."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nakamoto Y, Imai H, Yasuda T, Wakui H, Miura AB. A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 14: 2370-2378, 1999.","DOI":"10.1093\/ndt\/14.10.2370"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Soubrier M, Sauron C, Souweine B, et al. Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. Am J Kidney Dis 34: 633-638, 1999.","DOI":"10.1016\/S0272-6386(99)70386-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kobayashi T, Miura M, Niioka T, et al. Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide. Ther Drug Monit 40: 301-309, 2018.","DOI":"10.1097\/FTD.0000000000000499"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/23\/58_2882-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T22:46:39Z","timestamp":1575672399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/23\/58_2882-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2882-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}